Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by UK REACH Regulation SI 2019/758

# **SAFETY DATA SHEET**



FEIDOPUR PRIMER ZG23-G1 - All variants

### SECTION 1: Identification of the substance/mixture and of the company/ undertaking

### 1.1 Product identifier

Product name : FEIDOPUR PRIMER ZG23-G1 - All variants

**1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use**: Paint.

#### 1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

#### responsible for this SDS National contact

Teknos (UK) Limited, 7 Longlands Rd, Bicester, Oxfordshire OX26 5AH, United Kingdom. Tel. +44 (0) 1869 208005.

#### 1.4 Emergency telephone number

National advisory body/Poison Centre

Telephone number : NHS: 111

### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

Product definition : Mixture

**Classification according to UK CLP/GHS** 

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 STOT SE 3, H336 Aquatic Chronic 2, H411

The product is classified as hazardous according to UK CLP Regulation SI 2019/720 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

### 2.2 Label elements

Hazard pictograms



Signal word Hazard statements

- : Warning
- : H226 Flammable liquid and vapour.
  - H315 Causes skin irritation.
  - H317 May cause an allergic skin reaction.
  - H319 Causes serious eye irritation.
  - H336 May cause drowsiness or dizziness.
  - H411 Toxic to aquatic life with long lasting effects.

#### **Precautionary statements**

### **SECTION 2: Hazards identification**

| Prevention  | 210 - Keep<br>ources. No   | r protective gloves. Wear eye or face protection.<br>away from heat, hot surfaces, sparks, open flames and other ignition<br>smoking.<br>I release to the environment. |
|---|----------------------------|--|
| Response  | 391 - Colle                | ct spillage.   |
| Storage   | 403 + P23                  | 3 - Store in a well-ventilated place. Keep container tightly closed.   |
| Disposal  | •                          | ose of contents and container in accordance with all local, regional, international regulations.   |
| Supplemental label<br>elements  | Varning! Ha<br>reathe spra | zardous respirable droplets may be formed when sprayed. Do not<br>ay or mist.  |
| Annex XVII - Restrictions<br>on the manufacture,<br>placing on the market and<br>use of certain dangerous<br>substances, mixtures and<br>articles | lot applicab               | le.  |
| 2.3 Other hazards   |                            |  |
| Product meets the criteria<br>for PBT or vPvB according<br>to Regulation (EC) No.<br>1907/2006, Annex XIII  | his mixture<br>PvB.        | does not contain any substances that are assessed to be a PBT or a   |
| Other hazards which do  | lone known                 |  |

Other hazards which do not result in classification

### **SECTION 3: Composition/information on ingredients**

| 3.2 Mixtures : N                               | lixture  |                  |  |         |
|--|--|------------------|--|---------|
| Product/ingredient name                        | Identifiers  | %                | Classification   | Туре    |
| -Butyl acetate                                 | REACH #:<br>01-2119485493-29<br>EC: 204-658-1<br>CAS: 123-86-4<br>Index: 607-025-00-1  | ≥10 - ≤25        | Flam. Liq. 3, H226<br>STOT SE 3, H336<br>EUH066  | [1] [2] |
| Xylene   | REACH #:<br>01-2119488216-32<br>EC: 215-535-7<br>CAS: 1330-20-7<br>Index: 601-022-00-9 | <10              | Flam. Liq. 3, H226<br>Acute Tox. 4, H312<br>Acute Tox. 4, H332<br>Skin Irrit. 2, H315<br>Eye Irrit. 2, H319<br>STOT SE 3, H335<br>STOT RE 2, H373<br>(oral, inhalation)<br>Asp. Tox. 1, H304 | [1] [2] |
| Trizinc bis(orthophosphate)                    | REACH #:<br>01-2119485044-40<br>EC: 231-944-3<br>CAS: 7779-90-0<br>Index: 030-011-00-6 | ≤10              | Aquatic Acute 1, H400<br>(M=1)<br>Aquatic Chronic 1,<br>H410 (M=1)   | [1]     |
| titanium dioxide                               | REACH #:<br>01-2119489379-17<br>EC: 236-675-5<br>CAS: 13463-67-7                       | ≤10              | Carc. 2, H351<br>(inhalation)  | [1] [*] |
| 2-Methoxy-1-methylethyl acetate                | REACH #:<br>01-2119475791-29<br>EC: 203-603-9<br>CAS: 108-65-6<br>Index: 607-195-00-7  | ≤10              | Flam. Liq. 3, H226<br>STOT SE 3, H336  | [1] [2] |
| Solvent naphtha (petroleum), light<br>aromatic | REACH #:<br>01-2119455851-35<br>EC: 265-199-0<br>CAS: 64742-95-6                       | ≤5               | Flam. Liq. 3, H226<br>STOT SE 3, H335<br>STOT SE 3, H336<br>Asp. Tox. 1, H304  | [1]     |
|  | : 14/04/2023 Date of previous  | issue : 25/11/20 |  |         |
| FEIDOPUR PRIMER ZG23-G1 - All                  | variants   |                  | Label No :#54  | 29      |

|   | Index: 649-356-00-4  |      | Aquatic Chronic 2,<br>H411   |        |
|---|--|------|--|--------|
| Phenol, 4,4'-(1-methylethylidene)<br>bis-, polymer with 2,2'-[<br>1-methylethylidene)bis<br>4,1-phenyleneoxymethylene)]bis<br>oxirane | CAS: 25036-25-3  | ≤3   | EUH066<br>Skin Irrit. 2, H315<br>Eye Irrit. 2, H319<br>Skin Sens. 1, H317  | [1]    |
| Ethylbenzene  | REACH #:<br>01-2119489370-35<br>EC: 202-849-4<br>CAS: 100-41-4<br>Index: 601-023-00-4  | ≤3   | Flam. Liq. 2, H225<br>Acute Tox. 4, H332<br>STOT RE 2, H373<br>(hearing organs) (oral,<br>inhalation)<br>Asp. Tox. 1, H304                           | [1] [2 |
| 2-butoxyethyl acetate   | REACH #:<br>01-2119475112-47<br>EC: 203-933-3<br>CAS: 112-07-2                         | <1   | Acute Tox. 4, H302<br>Acute Tox. 4, H312<br>Acute Tox. 4, H332   | [1] [2 |
| Hexanoic acid, 2-ethyl-, zinc salt,<br>basic  | EC: 286-272-3<br>CAS: 85203-81-2   | ≤0.3 | Eye Irrit. 2, H319<br>Repr. 2, H361d<br>Aquatic Chronic 3,<br>H412   | [1]    |
| Zinc oxide  | REACH #:<br>01-2119463881-32<br>EC: 215-222-5<br>CAS: 1314-13-2<br>Index: 030-013-00-7 | ≤0.3 | Aquatic Acute 1, H400<br>(M=1)<br>Aquatic Chronic 1,<br>H410 (M=1)   | [1]    |
| oluene  | REACH #:<br>01-2119471310-51<br>EC: 203-625-9<br>CAS: 108-88-3                         | ≤0.1 | Flam. Liq. 2, H225<br>Skin Irrit. 2, H315<br>Repr. 2, H361d<br>STOT SE 3, H336<br>STOT RE 2, H373<br>Asp. Tox. 1, H304<br>Aquatic Chronic 3,<br>H412 | [1] [2 |
| Di-isobutyl ketone  | REACH #:<br>01-2119474441-41<br>EC: 203-620-1<br>CAS: 108-83-8<br>Index: 606-005-00-X  | ≤0.1 | Flam. Liq. 3, H226<br>STOT SE 3, H335  | [1] [2 |
| Fluorite  | EC: 238-575-7<br>CAS: 14542-23-5   | ≤0.1 | Not classified.  | [2]    |
| so-butanol  | REACH #:<br>01-2119484609-23<br>EC: 201-148-0<br>CAS: 78-83-1<br>Index: 603-108-00-1   | ≤0.1 | Flam. Liq. 3, H226<br>Skin Irrit. 2, H315<br>Eye Dam. 1, H318<br>STOT SE 3, H335<br>STOT SE 3, H336  | [1] [2 |
| outan-2-ol  | REACH #:<br>01-2119475146-36<br>EC: 201-158-5<br>CAS: 78-92-2<br>Index: 603-127-00-5   | ≤0.1 | Flam. Liq. 3, H226<br>Eye Irrit. 2, H319<br>STOT SE 3, H335<br>STOT SE 3, H336   | [1] [2 |
| 1-isocyanatosulphonyltoluene  | REACH #:<br>01-2119980050-47<br>EC: 223-810-8<br>CAS: 4083-64-1<br>Index: 615-012-00-7 | ≤0.1 | Skin Irrit. 2, H315<br>Eye Irrit. 2, H319<br>Resp. Sens. 1, H334<br>STOT SE 3, H335<br>EUH014  | [1] [2 |
| Methyl methacrylate   | REACH #:<br>01-2119452498-28<br>EC: 201-297-1<br>CAS: 80-62-6<br>Index: 607-035-00-6   | ≤0.1 | Flam. Liq. 2, H225<br>Skin Irrit. 2, H315<br>Skin Sens. 1, H317<br>STOT SE 3, H335   | [1] [2 |
| osyl chloride   | EC: 202-684-8<br>CAS: 98-59-9  | ≤0.1 | Skin Irrit. 2, H315<br>Eye Dam. 1, H318  | [1] [2 |
| Dibutyltindilaurate   | REACH #:   | <0.1 | Skin Corr. 1C, H314  | [1] [2 |

| 01-2119496068-27<br>EC: 201-039-8<br>CAS: 77-58-7 | Eye Dam. 1, H318<br>Skin Sens. 1, H317<br>Muta. 2, H341<br>Repr. 1B, H360<br>STOT SE 1, H370<br>STOT RE 1, H372<br>Aquatic Acute 1, H400<br>(M=1)<br>Aquatic Chronic 1,<br>H410 (M=1) |
|---|---|
|   | See Section 16 for<br>the full text of the H<br>statements declared<br>above.   |

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Туре

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter  $\leq$  10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

| Eye contact                | : | Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.   |
|----------------------------|---|---|
| Inhalation                 | : | Remove victim to fresh air and keep at rest in a position comfortable for breathing.<br>If it is suspected that fumes are still present, the rescuer should wear an appropriate<br>mask or self-contained breathing apparatus. If not breathing, if breathing is irregular<br>or if respiratory arrest occurs, provide artificial respiration or oxygen by trained<br>personnel. It may be dangerous to the person providing aid to give mouth-to-mouth<br>resuscitation. Get medical attention. If necessary, call a poison center or physician.<br>If unconscious, place in recovery position and get medical attention immediately.<br>Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or<br>waistband. |
| Skin contact               | : | Wash with plenty of soap and water. Remove contaminated clothing and shoes.<br>Wash contaminated clothing thoroughly with water before removing it, or wear<br>gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the<br>event of any complaints or symptoms, avoid further exposure. Wash clothing before<br>reuse. Clean shoes thoroughly before reuse.   |
| Ingestion                  | : | Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.                           |
| Protection of first-aiders | : | No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.   |

#### 4.2 Most important symptoms and effects, both acute and delayed Over-exposure signs/symptoms

### SECTION 4: First aid measures

| Eye contact  | : Adverse symptoms may include the following:<br>pain or irritation<br>watering<br>redness  |
|--------------|---|
| Inhalation   | : Adverse symptoms may include the following:<br>nausea or vomiting<br>headache<br>drowsiness/fatigue<br>dizziness/vertigo<br>unconsciousness |
| Skin contact | <ul> <li>Adverse symptoms may include the following:<br/>irritation<br/>redness</li> </ul>  |
| Ingestion    | : No specific data.   |

#### 4.3 Indication of any immediate medical attention and special treatment needed

| Notes to physician  | : Treat symptomatically. Contact poison treatment specialist immediately if large |
|---------------------|---|
|                     | quantities have been ingested or inhaled.   |
| Specific treatments | : No specific treatment.  |

### **SECTION 5: Firefighting measures**

| 5.1 Extinguishing media                           |    |  |
|---|----|--|
| Suitable extinguishing media                      | :  | Use dry chemical, CO <sub>2</sub> , water spray (fog) or foam.   |
| Unsuitable extinguishing media                    | :  | Do not use water jet.  |
| 5.2 Special hazards arising fr                    | om | the substance or mixture   |
| Hazards from the substance or mixture             | :  | Flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard.<br>In a fire or if heated, a pressure increase will occur and the container may burst, with<br>the risk of a subsequent explosion. This material is toxic to aquatic life with long<br>lasting effects. Fire water contaminated with this material must be contained and<br>prevented from being discharged to any waterway, sewer or drain. |
| Hazardous combustion<br>products                  | :  | Decomposition products may include the following materials:<br>carbon dioxide<br>carbon monoxide<br>sulfur oxides<br>phosphorus oxides<br>metal oxide/oxides   |
| 5.3 Advice for firefighters                       |    |  |
| Special protective actions for fire-fighters      | :  | Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.   |
| Special protective<br>equipment for fire-fighters | :  | Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.  |

### **SECTION 6: Accidental release measures**

6.1 Personal precautions, protective equipment and emergency procedures

| For non-emergency<br>personnel | : No action shall be taken involving any personal risk or without suitable training.<br>Evacuate surrounding areas. Keep unnecessary and unprotected personnel from<br>entering. Do not touch or walk through spilt material. Shut off all ignition sources.<br>No flares, smoking or flames in hazard area. Avoid breathing vapour or mist.<br>Provide adequate ventilation. Wear appropriate respirator when ventilation is<br>inadequate. Put on appropriate personal protective equipment. |
|--------------------------------|--|
|                                |  |

| Date of issue/Date of revision | : 14/04/2023 | Date of previous issue | : 25/11/2022 | Version  | : 2.01        | 5/23 |
|--------------------------------|--------------|------------------------|--------------|----------|---------------|------|
| FEIDOPUR PRIMER ZG23-G1 - A    | All variants |                        |              | Label No | <b>4</b> 5429 | )    |

### **SECTION 6: Accidental release measures**

| OLOTION 0. Acciden              |  |
|---------------------------------|--|
| For emergency responders        | : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".  |
| 6.2 Environmental precautions   | : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains<br>and sewers. Inform the relevant authorities if the product has caused environmental<br>pollution (sewers, waterways, soil or air). Water polluting material. May be harmful<br>to the environment if released in large quantities. Collect spillage.  |
| 6.3 Methods and material for    | containment and cleaning up  |
| Small spill                     | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.   |
| Large spill                     | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spill product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal. |
| 6.4 Reference to other sections | <ul> <li>See Section 1 for emergency contact information.</li> <li>See Section 8 for information on appropriate personal protective equipment.</li> <li>See Section 13 for additional waste treatment information.</li> </ul>  |

### **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

| Protective measures                    | : Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container. |
|--|---|
| Advice on general occupational hygiene | : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.   |

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

### Seveso Directive - Reporting thresholds

#### Danger criteria

Date of issue/Date of revision: 14/04/2023DFEIDOPUR PRIMER ZG23-G1 - All variants

023 Date of previous issue

| SECTION 7: Handling and storage |         |                                    |                          |  |  |
|---------------------------------|---------|------------------------------------|--------------------------|--|--|
| C                               | ategory | Notification and MAPP<br>threshold | Safety report threshold  |  |  |
| P:<br>E:                        | 5c<br>2 | 5000 tonne<br>200 tonne            | 50000 tonne<br>500 tonne |  |  |

### 7.3 Specific end use(s)

| Recommendations                      | : Not available. |
|--------------------------------------|------------------|
| Industrial sector specific solutions | : Not available. |

### **SECTION 8: Exposure controls/personal protection**

| -                               |  |
|---------------------------------|--|
| 1 Control parameters            |  |
| Occupational exposure limits    |  |
| -Butyl acetate                  | EH40/2005 WELs (United Kingdom (UK), 1/2020).                  |
| P Buly doolato                  | STEL: 966 mg/m <sup>3</sup> 15 minutes.                        |
|                                 | STEL: 200 ppm 15 minutes.                                      |
|                                 | TWA: 724 mg/m <sup>3</sup> 8 hours.                            |
|                                 | TWA: 150 ppm 8 hours.  |
| Xylene                          | EH40/2005 WELs (United Kingdom (UK), 1/2020). [xylene, o-,m    |
| ,                               | p- or mixed isomers] Absorbed through skin.                    |
|                                 | STEL: 441 mg/m <sup>3</sup> 15 minutes.                        |
|                                 | TWA: 50 ppm 8 hours.   |
|                                 | TWA: 220 mg/m <sup>3</sup> 8 hours.                            |
|                                 | STEL: 100 ppm 15 minutes.                                      |
| 2-Methoxy-1-methylethyl acetate | EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed         |
|                                 | through skin.  |
|                                 | STEL: 548 mg/m³ 15 minutes.                                    |
|                                 | TWA: 50 ppm 8 hours.   |
|                                 | TWA: 274 mg/m <sup>3</sup> 8 hours.                            |
|                                 | STEL: 100 ppm 15 minutes.                                      |
| Ethylbenzene                    | EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed         |
|                                 | through skin.  |
|                                 | STEL: 552 mg/m <sup>3</sup> 15 minutes.                        |
|                                 | STEL: 125 ppm 15 minutes.                                      |
|                                 | TWA: 100 ppm 8 hours.  |
|                                 | TWA: 441 mg/m <sup>3</sup> 8 hours.                            |
| 2-butoxyethyl acetate           | EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed         |
|                                 | through skin.  |
|                                 | TWA: 20 ppm 8 hours.   |
|                                 | STEL: 50 ppm 15 minutes.                                       |
|                                 | STEL: 332 mg/m³ 15 minutes.<br>TWA: 133 mg/m³ 8 hours.         |
| toluene                         | EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed         |
| loidene                         | through skin.  |
|                                 | STEL: 384 mg/m <sup>3</sup> 15 minutes.                        |
|                                 | TWA: 191 mg/m <sup>3</sup> 8 hours.                            |
|                                 | TWA: 50 ppm 8 hours.   |
|                                 | STEL: 100 ppm 15 minutes.                                      |
| Di-isobutyl ketone              | EH40/2005 WELs (United Kingdom (UK), 1/2020).                  |
|                                 | TWA: 25 ppm 8 hours.   |
|                                 | TWA: 148 mg/m <sup>3</sup> 8 hours.                            |
| Fluorite                        | EU OEL (Europe, 1/2022). [fluorides, inorganic] Notes: list of |
|                                 | indicative occupational exposure limit values                  |
|                                 | TWA: 2.5 mg/m <sup>3</sup> 8 hours.                            |
| iso-butanol                     | EH40/2005 WELs (United Kingdom (UK), 1/2020).                  |
|                                 | STEL: 231 mg/m <sup>3</sup> 15 minutes.                        |
|                                 | STEL: 75 ppm 15 minutes.                                       |
|                                 |  |
|                                 | TWA: 154 mg/m <sup>3</sup> 8 hours.                            |
|                                 | TWA: 154 mg/m <sup>3</sup> 8 hours.<br>TWA: 50 ppm 8 hours.    |
| butan-2-ol                      |  |

### **SECTION 8: Exposure controls/personal protection**

| SECTION 6. Exposure controls/personal protection |   |  |  |  |  |
|--|---|--|--|--|--|
|  | STEL: 150 ppm 15 minutes.                                     |  |  |  |  |
|  | TWA: 308 mg/m³ 8 hours.                                       |  |  |  |  |
|  | TWA: 100 ppm 8 hours.   |  |  |  |  |
| 4-isocyanatosulphonyltoluene                     | EH40/2005 WELs (United Kingdom (UK), 1/2020). [isocyanates,   |  |  |  |  |
|  | all, except methyl isocyanate as –NCO] Inhalation sensitiser. |  |  |  |  |
|  | STEL: 0.07 mg/m <sup>3</sup> , (as -NCO) 15 minutes.          |  |  |  |  |
|  | TWA: 0.02 mg/m³, (as -NCO) 8 hours.                           |  |  |  |  |
| Methyl methacrylate                              | EH40/2005 WELs (United Kingdom (UK), 1/2020).                 |  |  |  |  |
|  | STEL: 416 mg/m <sup>3</sup> 15 minutes.                       |  |  |  |  |
|  | STEL: 100 ppm 15 minutes.                                     |  |  |  |  |
|  | TWA: 208 mg/m <sup>3</sup> 8 hours.                           |  |  |  |  |
|  | TWA: 50 ppm 8 hours.  |  |  |  |  |
| tosyl chloride                                   | EH40/2005 WELs (United Kingdom (UK), 1/2020).                 |  |  |  |  |
| -  | STEL: 5 mg/m <sup>3</sup> 15 minutes.                         |  |  |  |  |
| Dibutyltindilaurate                              | EH40/2005 WELs (United Kingdom (UK), 1/2020). [tin            |  |  |  |  |
|  | compounds, organic, except cyhexatin (ISO) as Sn] Absorbed    |  |  |  |  |
|  | through skin.   |  |  |  |  |
|  | STEL: 0.2 mg/m³, (as Sn) 15 minutes.                          |  |  |  |  |
|  | TWA: 0.1 mg/m³, (as Sn) 8 hours.                              |  |  |  |  |
|  |   |  |  |  |  |

#### **Biological exposure indices**

No exposure indices known.

#### **Recommended monitoring** : Reference should be made to appropriate monitoring standards. Reference to national guidance documents for methods for the determination of hazardous procedures substances will also be required.

#### **DNELs/DMELs**

| Product/ingredient name | Туре | Exposure                 | Value                  | Population            | Effects  |
|-------------------------|------|--------------------------|------------------------|-----------------------|----------|
| n-Butyl acetate         | DNEL | Short term Oral          | 2 mg/kg<br>bw/day      | General population    | Systemic |
|                         | DNEL | Long term Oral           | 2 mg/kg<br>bw/day      | General<br>population | Systemic |
|                         | DNEL | Short term Dermal        | 6 mg/kg<br>bw/day      | General<br>population | Systemic |
|                         | DNEL | Short term Dermal        | 11 mg/kg<br>bw/day     | Workers               | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 35.7 mg/m <sup>3</sup> | General<br>population | Local    |
|                         | DNEL | Short term<br>Inhalation | 300 mg/m³              | General<br>population | Local    |
|                         | DNEL | Short term<br>Inhalation | 300 mg/m³              | General<br>population | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 300 mg/m³              | Workers               | Local    |
|                         | DNEL | Short term<br>Inhalation | 600 mg/m³              | Workers               | Local    |
|                         | DNEL | Short term<br>Inhalation | 600 mg/m³              | Workers               | Systemic |
|                         | DNEL | Long term Dermal         | 3.4 mg/kg<br>bw/day    | General<br>population | Systemic |
|                         | DNEL | Long term Dermal         | 7 mg/kg<br>bw/day      | Workers               | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 12 mg/m <sup>3</sup>   | General<br>population | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 48 mg/m³               | Workers               | Systemic |
| Xylene                  | DNEL | Long term<br>Inhalation  | 65.3 mg/m³             | General<br>population | Local    |
|                         | DNEL | Short term<br>Inhalation | 260 mg/m³              | General<br>population | Local    |
|                         | DNEL | Short term<br>Inhalation | 260 mg/m³              | General<br>population | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 221 mg/m³              | Workers               | Local    |
|                         | DNEL | Long term Oral           | 12.5 mg/               | General               | Systemic |

|  |      |                                | kg bw/day                    | population            |          |
|--|------|--------------------------------|------------------------------|-----------------------|----------|
|  | DNEL | Long term                      | 65.3 mg/m <sup>3</sup>       | General               | Systemic |
|  | DNE  | Inhalation                     | 105                          | population            |          |
|  | DNEL | Long term Dermal               | 125 mg/kg                    | General               | Systemic |
|  | DNEL | Long term Dermal               | bw/day<br>212 mg/kg          | population<br>Workers | Systemic |
|  | DNEL | Long term                      | bw/day<br>221 mg/m³          | Workers               | Systemic |
|  | DNEL | Inhalation<br>Short term       | 442 mg/m <sup>3</sup>        | Workers               | Local    |
|  | DNEL | Inhalation<br>Short term       | 442 mg/m <sup>3</sup>        | Workers               | Systemic |
| Trizinc bis(orthophosphate)                    | DNEL | Inhalation<br>Long term Oral   | 0.83 mg/                     | General               | Systemic |
|  | DNEL | Long term                      | kg bw/day<br>2.5 mg/m³       | population<br>General | Systemic |
|  | DNEL | Inhalation<br>Long term        | 5 mg/m³                      | population<br>Workers | Systemic |
|  | DNEL | Inhalation<br>Long term Dermal | 83 mg/kg                     | General               | Systemic |
|  | DNEL | Long term Dermal               | bw/day<br>83 mg/kg           | population<br>Workers | Systemic |
| 2-Methoxy-1-methylethyl acetate                | DNEL | Long term                      | bw/day<br>33 mg/m³           | General               | Local    |
|  | DNEL | Inhalation<br>Long term        | 33 mg/m³                     | population<br>General | Systemic |
|  | DNEL | Inhalation<br>Long term Oral   | 36 mg/kg                     | population<br>General | Systemic |
|  | DNEL | Long term                      | bw/day<br>275 mg/m³          | population<br>Workers | Systemic |
|  | DNEL | Inhalation<br>Long term Dermal | 320 mg/kg                    | General               | Systemic |
|  | DNEL | Short term                     | bw/day<br>550 mg/m³          | population<br>Workers | Local    |
|  |      | Inhalation                     |                              |                       |          |
|  | DNEL | Long term Dermal               | 796 mg/kg<br>bw/day          | Workers               | Systemic |
| Solvent naphtha (petroleum), light<br>aromatic | DNEL | Long term<br>Inhalation        | 0.41 mg/m <sup>3</sup>       | population            | Systemic |
|  | DNEL | Long term<br>Inhalation        | 1.9 mg/m³                    | Workers               | Systemic |
|  | DNEL | Long term<br>Inhalation        | 178.57 mg/<br>m³             | General population    | Local    |
|  | DNEL | Short term<br>Inhalation       | 640 mg/m <sup>3</sup>        | General population    | Local    |
|  | DNEL | Long term<br>Inhalation        | 837.5 mg/<br>m³              | Workers               | Local    |
|  | DNEL | Short term<br>Inhalation       | 1066.67<br>mg/m³             | Workers               | Local    |
|  | DNEL | Short term<br>Inhalation       | 1152 mg/<br>m <sup>3</sup>   | General<br>population | Systemic |
|  | DNEL | Short term<br>Inhalation       | 1286.4 mg/<br>m <sup>3</sup> | Workers               | Systemic |
| Ethylbenzene                                   | DNEL | Long term Oral                 | 1.6 mg/kg<br>bw/day          | General<br>population | Systemic |
|  | DNEL | Long term<br>Inhalation        | 15 mg/m³                     | General<br>population | Systemic |
|  | DNEL | Long term<br>Inhalation        | 77 mg/m³                     | Workers               | Systemic |
|  | DNEL | Long term Dermal               | 180 mg/kg<br>bw/day          | Workers               | Systemic |
|  | DNEL | Short term<br>Inhalation       | 293 mg/m <sup>3</sup>        | Workers               | Local    |
|  | DMEL | Long term<br>Inhalation        | 442 mg/m <sup>3</sup>        | Workers               | Local    |
|  | DMEL | Short term                     | 884 mg/m³                    | Workers               | Systemic |

|                                     |       | Inhalation                            |                        |                       |             |
|-------------------------------------|-------|---------------------------------------|------------------------|-----------------------|-------------|
| 2-butoxyethyl acetate               | DNEL  | Long term Oral                        | 8.6 mg/kg              | General               | Systemic    |
|                                     |       |                                       | bw/day                 | population            |             |
|                                     | DNEL  | Short term Oral                       | 36 mg/kg               | General               | Systemic    |
|                                     | DNEL  | Short term Dermal                     | bw/day<br>72 mg/kg     | population<br>General | Systemic    |
|                                     | DINCL | Short term Derma                      | bw/day                 | population            | Oysternic   |
|                                     | DNEL  | Long term                             | 80 mg/m <sup>3</sup>   | General               | Systemic    |
|                                     |       | Inhalation                            | 5                      | population            | ,           |
|                                     | DNEL  | Long term Dermal                      | 102 mg/kg<br>bw/day    | General population    | Systemic    |
|                                     | DNEL  | Short term Dermal                     | 120 mg/kg<br>bw/day    | Workers               | Systemic    |
|                                     | DNEL  | Long term<br>Inhalation               | 133 mg/m³              | Workers               | Systemic    |
|                                     | DNEL  | Long term Dermal                      | 169 mg/kg<br>bw/day    | Workers               | Systemic    |
|                                     | DNEL  | Short term<br>Inhalation              | 200 mg/m <sup>3</sup>  | General<br>population | Local       |
|                                     | DNEL  | Short term<br>Inhalation              | 333 mg/m³              | Workers               | Local       |
| Hexanoic acid, 2-ethyl-, zinc salt, | DNEL  | Long term Oral                        | 3.21 mg/               | General               | Systemic    |
| pasic                               |       |                                       | kg bw/day              | population            | 3,000,000   |
|                                     | DNEL  | Long term Dermal                      | 3.21 mg/               | General               | Systemic    |
|                                     |       |                                       | kg bw/day              | population            |             |
|                                     | DNEL  | Long term Dermal                      | 6.41 mg/<br>kg bw/day  | Workers               | Systemic    |
|                                     | DNEL  | Long term                             | 10.42 mg/              | General               | Systemic    |
|                                     |       | Inhalation                            | $m^3$                  | population            | C. retermin |
|                                     | DNEL  | Long term<br>Inhalation               | 20.83 mg/<br>m³        | Workers               | Systemic    |
| Zinc oxide                          | DNEL  | Long term                             | 0.5 mg/m <sup>3</sup>  | Workers               | Local       |
|                                     | DNEL  | Long term Oral                        | 0.83 mg/               | General               | Systemic    |
|                                     | DNEL  | Long term                             | kg bw/day<br>2.5 mg/m³ | population<br>General | Systemic    |
|                                     | DNEL  | Inhalation<br>Long term<br>Inhalation | 5 mg/m³                | population<br>Workers | Systemic    |
|                                     | DNEL  | Long term Dermal                      | 83 mg/kg               | General               | Systemic    |
|                                     | DNEL  | Long term Dermal                      | bw/day<br>83 mg/kg     | population<br>Workers | Systemic    |
| oluene                              | DNEL  | Long term Oral                        | bw/day<br>8.13 mg/     | General               | Systemic    |
|                                     |       |                                       | kg bw/day              | population            | 1 1         |
|                                     | DNEL  | Long term<br>Inhalation               | 56.5 mg/m <sup>3</sup> | General population    | Local       |
|                                     | DNEL  | Long term                             | 56.5 mg/m <sup>3</sup> | General               | Systemic    |
|                                     |       | Inhalation                            |                        | population            | 3,000,000   |
|                                     | DNEL  | Long term<br>Inhalation               | 192 mg/m³              | Workers               | Local       |
|                                     | DNEL  | Long term                             | 192 mg/m³              | Workers               | Systemic    |
|                                     | DNEL  | Long term Dermal                      | 226 mg/kg<br>bw/day    | General<br>population | Systemic    |
|                                     | DNEL  | Short term<br>Inhalation              | 226 mg/m <sup>3</sup>  | General<br>population | Local       |
|                                     | DNEL  | Short term<br>Inhalation              | 226 mg/m³              | General<br>population | Systemic    |
|                                     | DNEL  | Long term Dermal                      | 384 mg/kg<br>bw/day    | Workers               | Systemic    |
|                                     | DNEL  | Short term<br>Inhalation              | 384 mg/m <sup>3</sup>  | Workers               | Local       |
|                                     | DNEL  | Short term                            | 384 mg/m³              | Workers               | Systemic    |
| Di-isobutyl ketone                  | DNEL  | Inhalation<br>Long term Dermal        | 7.7 mg/kg              | Workers               | Systemic    |

|                              |       |                   | bw/day                 |                       |                 |
|------------------------------|-------|-------------------|------------------------|-----------------------|-----------------|
|                              | DNEL  | Long term         | 53 mg/m <sup>3</sup>   | Workers               | Systemic        |
|                              |       | Inhalation        | 00g,                   |                       |                 |
| iso-butanol                  | DNEL  | Long term         | 55 mg/m³               | General               | Local           |
|                              |       | Inhalation        | <u>-</u>               | population            |                 |
|                              | DNEL  | Long term         | 310 mg/m <sup>3</sup>  | Workers               | Local           |
|                              |       | Inhalation        | • • • • · · · ·        |                       |                 |
| butan-2-ol                   | DNEL  | Long term Oral    | 15 mg/kg               | General               | Systemic        |
|                              | DITL  | Long tonn oran    | bw/day                 | population            | ejetenne        |
|                              | DNEL  | Long term Dermal  | 203 mg/kg              | General               | Systemic        |
|                              | DITLE | Long tonn Donnar  | bw/day                 | population            | Cyclonno        |
|                              | DNEL  | Long term         | 213 mg/m <sup>3</sup>  | General               | Systemic        |
|                              | DITLE | Inhalation        | 210 mg/m               | population            | Cyclonno        |
|                              | DNEL  | Long term Dermal  | 405 mg/kg              | Workers               | Systemic        |
|                              | DINCE | Long term Derma   | bw/day                 | VVOIKei3              | Oysternic       |
|                              | DNEL  | Long term         | 600 mg/m <sup>3</sup>  | Workers               | Systemic        |
|                              | DINEL | Inhalation        | 000 mg/m               | VUINEIS               | Systemic        |
| 4-isocyanatosulphonyltoluene | DNEL  | Long term Oral    | 0.46 mg/               | General               | Systemic        |
| 4-isocyanalosulphonylloluene | DINEL | Long term Oral    | kg bw/day              | population            | Systemic        |
|                              | DNEL  | Long torm Dormol  | 0.46 mg/               | General               | Systemic        |
|                              | DINEL | Long term Dermal  | kg bw/day              | -                     | Systemic        |
|                              | DNEL  | Long torm         |                        | population<br>General | Svetemie        |
|                              | DNEL  | Long term         | 0.8 mg/m <sup>3</sup>  |                       | Systemic        |
|                              |       | Inhalation        | 0.00 mm m/             | population            | Curata mia      |
|                              | DNEL  | Long term Dermal  | 0.92 mg/               | Workers               | Systemic        |
|                              |       |                   | kg bw/day              | \A/a #ka #a           | Curata mia      |
|                              | DNEL  | Long term         | 3.24 mg/m <sup>3</sup> | Workers               | Systemic        |
|                              |       | Inhalation        | 0.0                    | 0.0.0.0.0.0.0         | O. un far un la |
| Methyl methacrylate          | DNEL  | Long term Oral    | 8.2 mg/kg              | General               | Systemic        |
|                              |       |                   | bw/day                 | population            |                 |
|                              | DNEL  | Short term        | 208 mg/m <sup>3</sup>  | General               | Local           |
|                              |       | Inhalation        |                        | population            |                 |
|                              | DNEL  | Short term        | 416 mg/m <sup>3</sup>  | Workers               | Local           |
|                              |       | Inhalation        |                        | <b>.</b> .            |                 |
|                              | DNEL  | Short term Dermal | 1.5 mg/cm <sup>2</sup> |                       | Local           |
|                              |       |                   |                        | population            |                 |
|                              | DNEL  | Long term Dermal  | 1.5 mg/cm <sup>2</sup> | General               | Local           |
|                              |       |                   |                        | population            |                 |
|                              | DNEL  | Short term Dermal | 1.5 mg/cm <sup>2</sup> | Workers               | Local           |
|                              | DNEL  | Long term Dermal  | 1.5 mg/cm <sup>2</sup> | Workers               | Local           |
|                              | DNEL  | Long term Dermal  | 8.2 mg/kg              | General               | Systemic        |
|                              |       |                   | bw/day                 | population            |                 |
|                              | DNEL  | Long term Dermal  | 13.67 mg/              | Workers               | Systemic        |
|                              |       |                   | kg bw/day              |                       |                 |
|                              | DNEL  | Long term         | 74.3 mg/m <sup>3</sup> | General               | Systemic        |
|                              |       | Inhalation        |                        | population            |                 |
|                              | DNEL  | Long term         | 104 mg/m³              | General               | Local           |
|                              |       | Inhalation        |                        | population            |                 |
|                              | DNEL  | Long term         | 208 mg/m <sup>3</sup>  | Workers               | Local           |
|                              |       | Inhalation        |                        |                       |                 |
|                              | DNEL  | Long term         | 348.4 mg/              | Workers               | Systemic        |
|                              |       | Inhalation        | m³                     |                       |                 |
| tosyl chloride               | DNEL  | Long term Dermal  | 0.5 mg/kg              | Workers               | Systemic        |
|                              |       | -                 | bw/day                 |                       | -               |
|                              | DNEL  | Long term         | 3.5 mg/m <sup>3</sup>  | Workers               | Systemic        |
|                              |       | Inhalation        | -                      |                       |                 |
| Dibutyltindilaurate          | DNEL  | Long term Oral    | 0.0031 mg/             | General               | Systemic        |
| -                            |       | _                 | kg bw/day              | population            | -               |
|                              | DNEL  | Long term         | 0.0046 mg/             | General               | Systemic        |
|                              |       | Inhalation        | m <sup>3</sup>         | population            |                 |
|                              | DNEL  | Short term        | 0.059 mg/              | Workers               | Systemic        |
|                              |       | Inhalation        | m <sup>3</sup>         |                       | .,              |
|                              | DNEL  | Short term Dermal | 0.5 mg/kg              | General               | Systemic        |
|                              |       |                   | bw/day                 | population            | 5,000,000       |
|                              | DNEL  | Short term Oral   | 0.02 mg/               | General               | Systemic        |
|                              |       |                   | kg bw/day              | population            |                 |
|                              | DNEL  | Long term         | 0.02 mg/m <sup>3</sup> | Workers               | Systemic        |
|                              |       |                   |                        |                       | 0,0001110       |

| SECTION 8: Exposure controls/personal protection |                   |                        |            |          |  |
|--|-------------------|------------------------|------------|----------|--|
|  | Inhalation        |                        |            |          |  |
| DNEL   | Short term        | 0.04 mg/m <sup>3</sup> | General    | Systemic |  |
|  | Inhalation        | -                      | population |          |  |
| DNEL   | Long term Dermal  | 0.16 mg/               | General    | Systemic |  |
|  |                   | kg bw/day              | population |          |  |
| DNEL   | Long term Dermal  | 0.43 mg/               | Workers    | Systemic |  |
|  |                   | kg bw/day              |            |          |  |
| DNEL   | Short term Dermal | 2.08 mg/               | Workers    | Systemic |  |
|  |                   | kg bw/day              |            |          |  |

#### **PNECs**

No PNECs available

| Appropriate engineering<br>controls | : Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.   |
|-------------------------------------|--|
| Individual protection meas          |  |
| Hygiene measures                    | : Wash hands, forearms and face thoroughly after handling chemical products,<br>before eating, smoking and using the lavatory and at the end of the working period<br>Appropriate techniques should be used to remove potentially contaminated clothin<br>Contaminated work clothing should not be allowed out of the workplace. Wash<br>contaminated clothing before reusing. Ensure that eyewash stations and safety<br>showers are close to the workstation location.   |
| Eye/face protection                 | : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.  |
| Skin protection                     |  |
| Hand protection                     | : Chemical-resistant, impervious gloves complying with an approved standard shou<br>be worn at all times when handling chemical products if a risk assessment indicate<br>this is necessary. Considering the parameters specified by the glove manufacture<br>check during use that the gloves are still retaining their protective properties. It<br>should be noted that the time to breakthrough for any glove material may be<br>different for different glove manufacturers. In the case of mixtures, consisting of<br>several substances, the protection time of the gloves cannot be accurately<br>estimated. |
|                                     | Recommendations : Wear suitable gloves tested to EN374.  |
|                                     | < 1 hour (breakthrough time): Nitrile gloves. thickness > 0.3 mm   |
|                                     | 1 - 4 hours (breakthrough time): $4H$ / Silver Shield® gloves.   |
| Body protection                     | : Personal protective equipment for the body should be selected based on the task<br>being performed and the risks involved and should be approved by a specialist<br>before handling this product. When there is a risk of ignition from static electricity<br>wear anti-static protective clothing. For the greatest protection from static<br>discharges, clothing should include anti-static overalls, boots and gloves.   |
| Other skin protection               | : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.  |
| Respiratory protection              | <ul> <li>Based on the hazard and potential for exposure, select a respirator that meets the<br/>appropriate standard or certification. Respirators must be used according to a<br/>respiratory protection program to ensure proper fitting, training, and other importar<br/>aspects of use.</li> <li>Filter type: A</li> </ul>  |

### **SECTION 8: Exposure controls/personal protection**

| Environmental | exposure |
|---------------|----------|
| controls      |          |

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

### **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

| <u>Appearance</u>                          |                  |
|--|------------------|
| Physical state                             | : Liquid.        |
| Colour                                     | : Various        |
| Odour                                      | : Slight         |
| Odour threshold                            | : Not available. |
| Melting point/freezing point               | : Not available. |
| Initial boiling point and<br>boiling range | :                |

| Ingredient name                             | °C         | °F         | Method   |
|---|------------|------------|----------|
| n-Butyl acetate                             | 126        | 258.8      | OECD 103 |
| Solvent naphtha (petroleum), light aromatic | 135 to 210 | 275 to 410 |          |

| Flammability (solid, gas)                    | : Not av                        | /ailable.        |            |           |  |
|--|---------------------------------|------------------|------------|-----------|--|
| Upper/lower flammability or explosive limits | : <mark>I∕</mark> ower<br>Upper | : 0.8%<br>: 7.6% |            |           |  |
| Flash point                                  | : Close                         | d cup: 25°C (77° | °F)        |           |  |
| Auto-ignition temperature                    | :                               |                  |            |           |  |
| Ingredient name                              |                                 | °C               | °F         | Method    |  |
| Solvent naphtha (petroleum), light aror      | natic                           | 280 to 470       | 536 to 878 |           |  |
| 2-Methoxy-1-methylethyl acetate              |                                 | 333              | 631.4      | DIN 51794 |  |
| Decomposition temperature                    | : Not av                        | /ailable.        |            |           |  |
| рН   | : Not ap                        | oplicable.       |            |           |  |
| Viscosity                                    | : Not av                        | /ailable.        |            |           |  |
| Solubility(ies)<br>Not available.            | :                               |                  |            |           |  |
| Solubility in water                          | : Not av                        | /ailable.        |            |           |  |

### Partition coefficient: n-octanol/ : Not applicable. water

ŝ,

#### Vapour pressure

|                          | V     | Vapour Pressure at 20°C |                | V     | Vapour pressure at 50° |        |  |
|--------------------------|-------|-------------------------|----------------|-------|------------------------|--------|--|
| Ingredient name          | mm Hg | kPa                     | Method         | mm Hg | kPa                    | Method |  |
| p-Butyl acetate          | 11.25 | 1.5                     | DIN EN 13016-2 |       |                        |        |  |
| Ethylbenzene             | 9.3   | 1.2                     |                |       |                        |        |  |
| Relative density         | : Not | available.              |                |       | ·                      |        |  |
| Density                  | : 1.5 | g/cm³                   |                |       |                        |        |  |
| Vapour density           | : Not | available.              |                |       |                        |        |  |
| Explosive properties     | : Not | available.              |                |       |                        |        |  |
| Oxidising properties     | : Not | available.              |                |       |                        |        |  |
| Particle characteristics |       |                         |                |       |                        |        |  |
| Median particle size     | : Not | applicable.             |                |       |                        |        |  |
| •                        |       |                         |                |       |                        |        |  |

Date of previous issue

| SECTION 10: Stabilit                     | SECTION 10: Stability and reactivity  |  |  |  |  |
|--|---|--|--|--|--|
| 10.1 Reactivity                          | : No specific test data related to reactivity available for this product or its ingredients.  |  |  |  |  |
| 10.2 Chemical stability                  | : The product is stable.  |  |  |  |  |
| 10.3 Possibility of hazardous reactions  | : Under normal conditions of storage and use, hazardous reactions will not occur.   |  |  |  |  |
| 10.4 Conditions to avoid                 | : Avoid all possible sources of ignition (spark or flame). Do not pressurise, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition. |  |  |  |  |
| 10.5 Incompatible materials              | : Reactive or incompatible with the following materials: oxidising materials  |  |  |  |  |
| 10.6 Hazardous<br>decomposition products | : Under normal conditions of storage and use, hazardous decomposition products should not be produced.  |  |  |  |  |

### **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

#### Acute toxicity

| Product/ingredient name         | Result                    | Species | Dose                    | Exposure |
|---------------------------------|---------------------------|---------|-------------------------|----------|
| R-Butyl acetate                 | LC50 Inhalation Vapour    | Rat     | 0.74 mg/l               | 4 hours  |
| -                               | LD50 Dermal               | Rabbit  | 14112 mg/kg             | -        |
|                                 | LD50 Oral                 | Rat     | 10760 mg/kg             | -        |
| Xylene                          | LC50 Inhalation Vapour    | Rat     | 21.7 mg/l               | 4 hours  |
| 2                               | LD50 Oral                 | Rat     | 4300 mg/kg              | -        |
| 2-Methoxy-1-methylethyl acetate | LD50 Dermal               | Rabbit  | >5 g/kg                 | -        |
|                                 | LD50 Oral                 | Rat     | 8532 mg/kg              | -        |
| Solvent naphtha                 | LD50 Oral                 | Rat     | 8400 mg/kg              | -        |
| (petroleum), light aromatic     |                           |         |                         |          |
| Ëthylbenzene                    | LC50 Inhalation Dusts and | Rat     | 29000 mg/l              | 4 hours  |
|                                 | mists                     |         |                         |          |
|                                 | LD50 Dermal               | Rabbit  | 15400 mg/kg             | -        |
|                                 | LD50 Oral                 | Rat     | 3500 mg/kg              | -        |
| 2-butoxyethyl acetate           | LD50 Dermal               | Rabbit  | 1500 mg/kg              | -        |
|                                 | LD50 Oral                 | Rat     | 2400 mg/kg              | -        |
| toluene                         | LC50 Inhalation Vapour    | Rat     | 49 g/m <sup>3</sup>     | 4 hours  |
|                                 | LD50 Oral                 | Rat     | 636 mg/kg               | -        |
| Di-isobutyl ketone              | LD50 Dermal               | Rabbit  | 16120 mg/kg             | -        |
| ,                               | LD50 Oral                 | Rat     | 5750 mg/kg              | -        |
| iso-butanol                     | LC50 Inhalation Vapour    | Rat     | 19200 mg/m <sup>3</sup> | 4 hours  |
|                                 | LD50 Dermal               | Rabbit  | 3400 mg/kg              | -        |
|                                 | LD50 Oral                 | Rat     | 2460 mg/kg              | -        |
| butan-2-ol                      | LC50 Inhalation Gas.      | Rat     | 8000 ppm                | 4 hours  |
|                                 | LC50 Inhalation Vapour    | Rat     | 48500 mg/m <sup>3</sup> | 4 hours  |
|                                 | LD50 Oral                 | Rat     | 2054 mg/kg              | -        |
| 4-isocyanatosulphonyltoluene    | LD50 Oral                 | Rat     | 2234 mg/kg              | -        |
| Methyl methacrylate             | LC50 Inhalation Vapour    | Rat     | 78000 mg/m <sup>3</sup> | 4 hours  |
|                                 | LD50 Dermal               | Rabbit  | >5 g/kg                 | -        |
|                                 | LD50 Oral                 | Rat     | 7872 mg/kg              | -        |
| Dibutyltindilaurate             | LD50 Oral                 | Rat     | 175 mg/kg               | -        |

#### Conclusion/Summary

: Based on available data, the classification criteria are not met.

#### Acute toxicity estimates

| Route                          | ATE value                     |
|--------------------------------|-------------------------------|
| Permal<br>Inhalation (vapours) | 13890.64 mg/kg<br>113.85 mg/l |
|                                | 110.00 mg/1                   |

Irritation/Corrosion

| Date | of | issue | /Date | of | revisio | 1 |
|------|----|-------|-------|----|---------|---|
|      |    |       |       |    |         |   |

#### vical aginal informati T

| Product/ingredient name      | Result                         | Species            | Score       | Exposure           | Observatio      |
|------------------------------|--------------------------------|--------------------|-------------|--------------------|-----------------|
| -Butyl acetate               | Eyes - Moderate irritant       | Rabbit             | -           | 100 mg             | -               |
| 5                            | Skin - Moderate irritant       | Rabbit             | -           | 24 hours 500       | -               |
|                              |                                |                    |             | mg                 |                 |
| (ylene                       | Eyes - Mild irritant           | Rabbit             | -           | 87 mg              | -               |
| <b>y</b>                     | Eyes - Severe irritant         | Rabbit             | -           | 24 hours 5         | -               |
|                              |                                |                    |             | mg                 |                 |
|                              | Skin - Mild irritant           | Rat                | -           | 8 hours 60 uL      | -               |
|                              | Skin - Moderate irritant       | Rabbit             | -           | 100 %              | -               |
|                              | Skin - Moderate irritant       | Rabbit             | -           | 24 hours 500       | -               |
|                              |                                |                    |             | mg                 |                 |
| tanium dioxide               | Skin - Mild irritant           | Human              | -           | 72 hours 300       | -               |
|                              |                                |                    |             | ug l               |                 |
| olvent naphtha (petroleum),  | Eyes - Mild irritant           | Rabbit             | -           | 24 hours 100       | -               |
| ght aromatic                 |                                |                    |             | uL                 |                 |
| thylbenzene                  | Eyes - Severe irritant         | Rabbit             | -           | 500 mg             | -               |
|                              | Skin - Mild irritant           | Rabbit             | -           | 24 hours 15        | -               |
|                              |                                | 1 COD DIT          |             | mg                 |                 |
| -butoxyethyl acetate         | Eyes - Mild irritant           | Rabbit             | -           | 24 hours 500       | -               |
|                              | Lycc mid interne               | 1 COD DIT          |             | mg                 |                 |
|                              | Skin - Mild irritant           | Rabbit             | -           | 500 mg             | -               |
| inc oxide                    | Eyes - Mild irritant           | Rabbit             | _           | 24 hours 500       | -               |
|                              |                                | 1 COD DIT          |             | mg                 |                 |
|                              | Skin - Mild irritant           | Rabbit             | -           | 24 hours 500       | -               |
|                              |                                | Rubbit             |             | mg                 |                 |
| luene                        | Eyes - Mild irritant           | Rabbit             | -           | 0.5 minutes        | _               |
| Jache                        | Lyco wind initiant             | Rubbit             |             | 100 mg             |                 |
|                              | Eyes - Mild irritant           | Rabbit             | -           | 870 ug             | _               |
|                              | Eyes - Severe irritant         | Rabbit             |             | 24 hours 2         | -               |
|                              | Lyes - Gevere initalit         | Rabbit             | -           | mg                 | -               |
|                              | Skin - Mild irritant           | Pig                | -           | 24 hours 250       | -               |
|                              |                                | Fig                | -           | uL                 | -               |
|                              | Skin - Mild irritant           | Rabbit             | -           | 435 mg             | _               |
|                              | Skin - Moderate irritant       | Rabbit             | -           | 24 hours 20        | -               |
|                              | Skill - Moderate initalit      | Nabbit             | -           |                    | -               |
|                              | Skin - Moderate irritant       | Rabbit             |             | mg<br>500 mg       |                 |
| i-isobutyl ketone            | Eyes - Mild irritant           | Human              |             | 15 minutes         | -               |
| -isobutyi ketone             |                                | Tuman              | -           | 25 ppm             | -               |
|                              | Eyes - Mild irritant           | Rabbit             | _           | 500 mg             | _               |
|                              | Skin - Mild irritant           | Rabbit             | _           | 24 hours 10        | _               |
|                              |                                | Rabbit             | -           | mg                 | -               |
|                              | Skin - Mild irritant           | Rabbit             | -           | 500 mg             | _               |
| utan-2-ol                    | Eyes - Severe irritant         | Rabbit             |             | 0.1 MI             | _               |
| -isocyanatosulphonyltoluene  | Eyes - Moderate irritant       | Rabbit             | -           | 100 uL             | -               |
| lisocyalialosulphonylloldene | Skin - Mild irritant           | Rabbit             |             | 24 hours 500       | -               |
|                              |                                | Tabbit             | -           | uL                 | -               |
| libutyltindilaurate          | Eyes - Moderate irritant       | Rabbit             | 1_          | u∟<br>24 hours 100 | -               |
|                              |                                | Tabbit             | -           | mg                 | -               |
|                              | Skin - Severe irritant         | Rabbit             | _           | 500 mg             | -               |
|                              | Skill - Severe illitant        | TADDIL             | -           | Joo nig            |                 |
| onclusion/Summary            | : Causes skin irritation.      |                    |             |                    |                 |
| ensitisation                 |                                |                    |             |                    |                 |
|                              | May aquad an allergia akin     | reaction           |             |                    |                 |
|                              | : May cause an allergic skin   |                    |             |                    |                 |
| <u>utagenicity</u>           |                                |                    |             |                    |                 |
| onclusion/Summary            | : Based on available data, th  | e classification c | riteria are | not met.           |                 |
| arcinogenicity               | ,                              |                    |             |                    |                 |
|                              |                                | -l                 |             |                    | 1 in            |
|                              | arcinogenic hazard of this pro |                    |             | e dust is inhaled  | a in quantities |
| • • •                        | nt of particle clearance mecha | •                  |             |                    |                 |
| onclusion/Summary            | : Based on available data, th  | e classification c | riteria are | not met.           |                 |
| eproductive toxicity         |                                |                    |             |                    |                 |
|                              |                                |                    | itoria      | not mot            |                 |
|                              | : Based on available data, th  | e classification c | iteria are  | not met.           |                 |
| and a second added           |                                |                    |             |                    |                 |
| eratogenicity                |                                |                    |             |                    |                 |

### **SECTION 11: Toxicological information**

#### **Conclusion/Summary** : Based on available data, the classification criteria are not met.

#### Specific target organ toxicity (single exposure)

| Product/ingredient name                     | Category   | Route of exposure | Target organs                   |
|---|------------|-------------------|---------------------------------|
| h-Butyl acetate                             | Category 3 | -                 | Narcotic effects                |
| Xylene                                      | Category 3 | -                 | Respiratory tract<br>irritation |
| 2-Methoxy-1-methylethyl acetate             | Category 3 | -                 | Narcotic effects                |
| Solvent naphtha (petroleum), light aromatic | Category 3 | -                 | Respiratory tract<br>irritation |
|   | Category 3 |                   | Narcotic effects                |
| toluene                                     | Category 3 | -                 | Narcotic effects                |
| Di-isobutyl ketone                          | Category 3 | -                 | Respiratory tract<br>irritation |
| iso-butanol                                 | Category 3 | -                 | Respiratory tract<br>irritation |
|   | Category 3 |                   | Narcotic effects                |
| butan-2-ol                                  | Category 3 | -                 | Respiratory tract<br>irritation |
|   | Category 3 |                   | Narcotic effects                |
| 4-isocyanatosulphonyltoluene                | Category 3 | -                 | Respiratory tract<br>irritation |
| Methyl methacrylate                         | Category 3 | -                 | Respiratory tract<br>irritation |
| Dibutyltindilaurate                         | Category 1 | -                 | -                               |

#### Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category | Route of exposure | Target organs  |
|-------------------------|----------|-------------------|----------------|
| Xylene                  |          | oral, inhalation  | -              |
| Ethylbenzene            |          | oral, inhalation  | hearing organs |
| toluene                 |          | -                 | -              |
| Dibutyltindilaurate     |          | -                 | -              |

#### **Aspiration hazard**

| Product/ingredient name                     | Result                         |
|---|--------------------------------|
| <b>X</b> ylene                              | ASPIRATION HAZARD - Category 1 |
| Solvent naphtha (petroleum), light aromatic | ASPIRATION HAZARD - Category 1 |
| Ethylbenzene                                | ASPIRATION HAZARD - Category 1 |
| toluene                                     | ASPIRATION HAZARD - Category 1 |

#### Information on likely routes : Not available.

#### of exposure

### Potential acute health effects

| Eye contact  | : Causes serious eye irritation.  |
|--------------|---|
| Inhalation   | : Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness. |
| Skin contact | : Causes skin irritation. May cause an allergic skin reaction.                          |
| Ingestion    | : Can cause central nervous system (CNS) depression.                                    |

#### Symptoms related to the physical, chemical and toxicological characteristics

| Eye contact : Adverse sy<br>pain or irrit<br>watering<br>redness | /mptoms may include the following:<br>ation |
|--|---|
|--|---|

: 25/11/2022

## **SECTION 11: Toxicological information**

| Inhalation                  | •                 | rse symptoms may include the following:  |
|-----------------------------|-------------------|--|
|                             | nause<br>heada    | ea or vomiting   |
|                             |                   | siness/fatigue   |
|                             | dizzin            | ess/vertigo  |
| Okin contect                |                   | nsciousness  |
| Skin contact                | irritati<br>redne |  |
| Ingestion                   |                   | pecific data.  |
| Delayed and immediate effe  | s as wel          | I as chronic effects from short and long-term exposure                                   |
| <u>Short term exposure</u>  |                   |  |
| Potential immediate effects | : Not a           | vailable.  |
| Potential delayed effects   | : Not a           | vailable.  |
| Long term exposure          |                   |  |
| Potential immediate effects | : Not a           | vailable.  |
| Potential delayed effects   | : Not a           | vailable.  |
| Potential chronic health ef | <u>cts</u>        |  |
| Not available.              |                   |  |
| Conclusion/Summary          | : Not a           | vailable.  |
| General                     |                   | sensitized, a severe allergic reaction may occur when subsequently exposed y low levels. |
| Carcinogenicity             | : No kr           | nown significant effects or critical hazards.  |
| Mutagenicity                | : No kr           | nown significant effects or critical hazards.  |
| Reproductive toxicity       | : No kr           | nown significant effects or critical hazards.  |
|                             |                   |  |

#### Other information

: Not available.

## **SECTION 12: Ecological information**

| 1 | 2. | 1 | То | xi | ci | ty |
|---|----|---|----|----|----|----|
|   |    |   |    |    |    | -  |

| Product/ingredient name                     | Result                                   | Species  | Exposure            |
|---|--|--|---------------------|
| p-Butyl acetate                             | Acute LC50 32 mg/l Marine water          | Crustaceans - Brine shrimp -<br>Artemia salina   | 48 hours            |
|   | Acute LC50 18000 µg/l Fresh water        | Fish - Fathead minnow -<br>Pimephales promelas   | 96 hours            |
| Trizinc bis(orthophosphate)                 | Acute EC50 0.32 mg/l                     | Algae - Selenastrum capricornutum  | 72 hours            |
|   | Acute EC50 0.96 mg/l                     | Crustaceans - Ceriodaphnia<br>dubia  | 48 hours            |
| titanium dioxide                            | Acute LC50 3 mg/l Fresh water            | Crustaceans - Water flea -<br>Ceriodaphnia dubia - Neonate                             | 48 hours            |
|   | Acute LC50 6.5 mg/l Fresh water          | Daphnia - Water flea - Daphnia pulex - Neonate   | 48 hours            |
|   | Acute LC50 >1000000 μg/l Marine<br>water | Fish - Mummichog - Fundulus heteroclitus   | 96 hours            |
| Solvent naphtha (petroleum), light aromatic | Acute EC50 3.2 mg/l                      | Daphnia  | 48 hours            |
| 0   | Acute LC50 9.2 mg/l                      | Fish   | 96 hours            |
| Zinc oxide                                  | Acute IC50 46 µg/l Fresh water           | Algae - Green algae -<br>Pseudokirchneriella subcapitata<br>- Exponential growth phase | 72 hours            |
|   | Acute IC50 1.85 mg/l Marine water        | Algae - Diatom - Skeletonema<br>costatum   | 96 hours            |
|   | Acute LC50 98 µg/l Fresh water           | Daphnia - Water flea - Daphnia   | 48 hours            |
| ate of issue/Date of revision               | : 14/04/2023 Date of previous issue      | : 25/11/2022 Version   | : 2.01 <b>17/23</b> |
| EIDOPUR PRIMER ZG23-G1                      | - All variants                           | Label No   | #5429               |

|                     |                                     | magna Naonata  |          |
|---------------------|-------------------------------------|--|----------|
|                     | Acute LC50 1.1 ppm Fresh water      | magna - Neonate<br>Fish - Rainbow trout,donaldson<br>trout - Oncorhynchus mykiss | 96 hours |
| toluene             | Acute EC50 12500 µg/l Fresh water   | Algae - Green algae -<br>Pseudokirchneriella subcapitata                         | 72 hours |
|                     | Acute EC50 11600 µg/l Fresh water   | Crustaceans - Scud -<br>Gammarus pseudolimnaeus -<br>Adult                       | 48 hours |
|                     | Acute EC50 5.56 mg/l Fresh water    | Daphnia - Water flea - Daphnia<br>magna - Neonate                                | 48 hours |
|                     | Acute LC50 5500 µg/l Fresh water    | Fish - Coho salmon,silver<br>salmon - Oncorhynchus kisutch<br>- Fry              | 96 hours |
|                     | Chronic NOEC 1000 µg/l Fresh water  | Daphnia - Water flea - Daphnia<br>magna  | 21 days  |
| iso-butanol         | Acute LC50 600 mg/l Marine water    | Crustaceans - Brine shrimp -<br>Artemia salina                                   | 48 hours |
|                     | Acute LC50 1030000 µg/l Fresh water | Daphnia - Water flea - Daphnia<br>magna - Neonate                                | 48 hours |
|                     | Acute LC50 1330000 µg/l Fresh water | Fish - Rainbow trout,donaldson<br>trout - Oncorhynchus mykiss                    | 96 hours |
| butan-2-ol          | Acute EC50 4227000 µg/l Fresh water | Daphnia - Water flea - Daphnia<br>magna  | 48 hours |
|                     | Acute LC50 3670000 µg/l Fresh water | Fish - Fathead minnow -<br>Pimephales promelas                                   | 96 hours |
| Methyl methacrylate | Acute LC50 130000 µg/l Fresh water  | Fish - Fathead minnow -<br>Pimephales promelas - Adult                           | 96 hours |
| Dibutyltindilaurate | Chronic EC10 >2 mg/l Fresh water    | Algae - Green algae -<br>Scenedesmus subspicatus                                 | 96 hours |

#### 12.2 Persistence and degradability

| Product/ingredient name | Test   | Result              |      | Dose | Inoculum         |
|-------------------------|--|---------------------|------|------|------------------|
| iso-butanol             | -  | 74 % - Readily - 28 | days | -    | -                |
| Conclusion/Summary      | : This product has not been tested for biodegradation. |                     |      |      |                  |
| Product/ingredient name | Aquatic half-life                                      | Aquatic half-life   |      | S    | Biodegradability |
| so-butanol              | -  |                     | -    |      | Readily          |

#### 12.3 Bioaccumulative potential

| Product/ingredient name                     | LogPow | BCF         | Potential |
|---|--------|-------------|-----------|
| <b>p</b> -Butyl acetate                     | 2.3    | -           | low       |
| Xylene                                      | 3.12   | 8.1 to 25.9 | low       |
| Trizinc bis(orthophosphate)                 | -      | 60960       | high      |
| 2-Methoxy-1-methylethyl acetate             | 1.2    | -           | low       |
| Solvent naphtha (petroleum), light aromatic | -      | 10 to 2500  | high      |
| Ethylbenzene                                | 3.6    | -           | low       |
| 2-butoxyethyl acetate                       | 1.51   | -           | low       |
| Hexanoic acid, 2-ethyl-, zinc salt, basic   | -      | 60960       | high      |
| Zinc oxide                                  | -      | 28960       | high      |
| toluene                                     | 2.73   | 90          | low       |
| Di-isobutyl ketone                          | 3.71   | -           | low       |
| iso-butanol                                 | 1      | -           | low       |
| butan-2-ol                                  | 0.61   | -           | low       |
| Methyl methacrylate                         | 1.38   | -           | low       |
| Dibutyltindilaurate                         | 4.44   | 2.91        | low       |

Date of issue/Date of revision: 14/04/202FEIDOPUR PRIMER ZG23-G1 - All variants

: 14/04/2023 Date of previous issue

: 25/11/2022

### **SECTION 12: Ecological information**

| 12.4 Mobility in soil                               |                  |
|---|------------------|
| Soil/water partition coefficient (K <sub>oc</sub> ) | : Not available. |
| Mobility  | : Not available. |

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

**12.6 Other adverse effects** : No known significant effects or critical hazards.

### SECTION 13: Disposal considerations

| -                                 |   |
|-----------------------------------|---|
| 13.1 Waste treatment method       | ods   |
| Product                           |   |
| Methods of disposal               | : The generation of waste should be avoided or minimised wherever possible.<br>Disposal of this product, solutions and any by-products should at all times comply<br>with the requirements of environmental protection and waste disposal legislation and<br>any regional local authority requirements. Dispose of surplus and non-recyclable<br>products via a licensed waste disposal contractor. Waste should not be disposed of<br>untreated to the sewer unless fully compliant with the requirements of all authorities<br>with jurisdiction. |
| Hazardous waste                   | : The classification of the product may meet the criteria for a hazardous waste.  |
| European waste<br>catalogue (EWC) | : 080111*   |
| Packaging                         |   |
| Methods of disposal               | : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.  |
| Special precautions               | : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.         |

### **SECTION 14: Transport information**

|                                    | ADR/RID | ADN    | IMDG   | IATA  |
|------------------------------------|---------|--------|--------|---|
| 14.1 UN number                     | UN1263  | UN1263 | UN1263 | UN1263  |
| 14.2 UN proper shipping name       | PAINT   | PAINT  | PAINT  | PAINT   |
| 14.3 Transport<br>hazard class(es) |         |        |        | 3   |
| 14.4 Packing<br>group              |         | 111    | 111    | 111   |
| 14.5<br>Environmental<br>hazards   | Yes.    | Yes.   | Yes.   | Yes. The<br>environmentally<br>hazardous substance<br>mark is not required. |

**Additional information** 

| SECTION 14: Transp  | rt information   |
|---|--|
| ADR/RID   | <ul> <li>The environmentally hazardous substance mark is not required when transported in sizes of ≤5 L or ≤5 kg.</li> <li><u>Tunnel code</u> (D/E)</li> </ul>   |
| ADN   | The environmentally hazardous substance mark is not required when transported in<br>sizes of ≤5 L or ≤5 kg.  |
| IMDG  | The marine pollutant mark is not required when transported in sizes of $\leq$ 5 L or $\leq$ 5 k  |
| ΙΑΤΑ  | The environmentally hazardous substance mark may appear if required by other transportation regulations.   |
| 14.6 Special precautions for user                         | <b>Transport within user's premises:</b> always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do i the event of an accident or spillage. |
| 14.7 Transport in bulk<br>according to IMO<br>instruments | Not relevant/applicable due to nature of the product.  |
| SECTION 15: Regula  | ory information  |

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture <u>UK (GB)/REACH</u>

#### Annex XIV - List of substances subject to authorisation

#### Annex XIV

None of the components are listed.

#### Substances of very high concern

None of the components are listed.

#### **Ozone depleting substances**

Not listed.

#### Prior Informed Consent (PIC)

Not listed.

#### Persistent Organic Pollutants

Not listed.

#### Annex XVII - Restrictions : Not applicable. on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

#### Seveso Directive

This product is controlled under the Seveso Directive.

#### Danger criteria

| Category  |  |
|-----------|--|
| P5c<br>E2 |  |
|           |  |

| EU regulations  |   |            |
|---|---|------------|
| Industrial emissions<br>(integrated pollution<br>prevention and control) -<br>Air   | : | Not listed |
| Industrial emissions<br>(integrated pollution<br>prevention and control) -<br>Water | : | Not listed |

: 25/11/2022

### **SECTION 15: Regulatory information**

#### **International regulations**

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

#### **Montreal Protocol**

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

#### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

#### **UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

#### **15.2 Chemical safety** assessment

: This product contains substances for which Chemical Safety Assessments are still required.

### **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

| Abbreviations and<br>acronyms | : ATE = Acute Toxicity Estimate<br>GB CLP = UK CLP (EC No 1272/2008) on the Classification, Labelling and<br>Packaging of Substances and Mixtures as amended by (EU Exit) Regulations 2019<br>No. 720 and amendments<br>DMEL = Derived Minimal Effect Level<br>DNEL = Derived No Effect Level<br>EUH statement = GB CLP-specific Hazard statement<br>N/A = Not available<br>PBT = Persistent, Bioaccumulative and Toxic<br>PNEC = Predicted No Effect Concentration<br>RRN = REACH Registration Number<br>SGG = Segregation Group |
|-------------------------------|---|
|                               | vPvB = Very Persistent and Very Bioaccumulative   |

#### Procedure used to derive the classification

| Classification          | Justification         |
|-------------------------|-----------------------|
| Flam. Liq. 3, H226      | On basis of test data |
| Skin Irrit. 2, H315     | Calculation method    |
| Eye Irrit. 2, H319      | Calculation method    |
| Skin Sens. 1, H317      | Calculation method    |
| STOT SE 3, H336         | Calculation method    |
| Aquatic Chronic 2, H411 | Calculation method    |

#### Full text of abbreviated H statements

|                    |  |         |        |       | ٦ |
|--------------------|--|---------|--------|-------|---|
| H225               | Highly flammable liquid and vapour.  |         |        |       |   |
| H226               | Flammable liquid and vapour.   |         |        |       |   |
| H302               | Harmful if swallowed.  |         |        |       |   |
| H304               | May be fatal if swallowed and enters airways.                              |         |        |       |   |
| H312               | Harmful in contact with skin.  |         |        |       |   |
| H314               | Causes severe skin burns and eye damage.                                   |         |        |       |   |
| H315               | Causes skin irritation.  |         |        |       |   |
| H317               | May cause an allergic skin reaction.                                       |         |        |       |   |
| H318               | Causes serious eye damage.   |         |        |       |   |
| H319               | Causes serious eye irritation.   |         |        |       |   |
| H332               | Harmful if inhaled.  |         |        |       |   |
| H334               | May cause allergy or asthma symptoms or breathing difficulties if inhaled. |         |        |       |   |
| H335               | May cause respiratory irritation.  |         |        |       |   |
| H336               | May cause drowsiness or dizziness.   |         |        |       |   |
| H341               | Suspected of causing genetic defects.                                      |         |        |       |   |
| H351               | Suspected of causing cancer.   |         |        |       |   |
| H360               | May damage fertility or the unborn child.                                  |         |        |       |   |
| Date of issue/Date | e of revision : 14/04/2023 Date of previous issue : 25/11/2022             | Version | : 2.01 | 21/23 |   |

| SECTION 16: Other information |  |  |
|-------------------------------|--|--|
| H361d                         | Suspected of damaging the unborn child.                            |  |
| H370                          | Causes damage to organs.   |  |
| H372                          | Causes damage to organs through prolonged or repeated exposure.    |  |
| H373                          | May cause damage to organs through prolonged or repeated exposure. |  |
| H400                          | Very toxic to aquatic life.  |  |
| H410                          | Very toxic to aquatic life with long lasting effects.              |  |
| H411                          | Toxic to aquatic life with long lasting effects.                   |  |
| H412                          | Harmful to aquatic life with long lasting effects.                 |  |
| EUH014                        | Reacts violently with water.                                       |  |
| EUH066                        | Repeated exposure may cause skin dryness or cracking.              |  |

#### Full text of classifications

| Acute Tox. 4           | ACUTE TOXICITY - Category 4                                     |
|------------------------|---|
| Aquatic Acute 1        | SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1                  |
| Aquatic Chronic 1      | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1                 |
| Aquatic Chronic 2      | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2                 |
| Aquatic Chronic 3      | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3                 |
| Asp. Tox. 1            | ASPIRATION HAZARD - Category 1                                  |
| Carc. 2                | CARCINOGENICITY - Category 2                                    |
| Eye Dam. 1             | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1                  |
| Eye Irrit. 2           | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2                  |
| Flam. Liq. 2           | FLAMMABLE LIQUIDS - Category 2                                  |
| Flam. Liq. 3           | FLAMMABLE LIQUIDS - Category 3                                  |
| Muta. 2                | GERM CELL MUTAGENICITY - Category 2                             |
| Repr. 1B               | REPRODUCTIVE TOXICITY - Category 1B                             |
| Repr. 2                | REPRODUCTIVE TOXICITY - Category 2                              |
| Resp. Sens. 1          | RESPIRATORY SENSITISATION - Category 1                          |
| Skin Corr. 1C          | SKIN CORROSION/IRRITATION - Category 1C                         |
| Skin Irrit. 2          | SKIN CORROSION/IRRITATION - Category 2                          |
| Skin Sens. 1           | SKIN SENSITISATION - Category 1                                 |
| STOT RE 1              | SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 1 |
| STOT RE 2              | SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2 |
| STOT SE 1              | SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 1   |
| STOT SE 3              | SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3   |
| Date of issue/ Date of | : 14/04/2023  |
| revision               |   |
| Date of previous issue | e : 25/11/2022  |
|                        |   |

: 2.01

EIDOPUR PRIMER ZG23-G1

All variants

#### Notice to reader

Version

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision: 14/04/2023DFEIDOPUR PRIMER ZG23-G1 - All variants

: 14/04/2023 Date of previous issue